Last reviewed · How we verify
A Study of JNJ-69095897 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of JNJ-69095897 versus placebo and to characterize the pharmacokinetic (PK) of JNJ-69095897 in blood, plasma, cerebrospinal fluid (CSF) and urine after single or divided oral dose administration in healthy participants.
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 48 |
| Start date | Wed Jun 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Feb 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- JNJ-69095897
- Placebo
Countries
Netherlands